Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice

Molecular Pharmaceutics

Volumn 6, Issue 1, 2009, Pages 246-254

  Elbayoumi, Tamer A ^a,b   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b Atrium Medical Corporation   (United States)

Author keywords

scintigraphy; Anticancer antibody; Doxorubicin; Long circulating liposomes; Metastases; Tumor growth inhibition; Tumor targeting

Indexed keywords

DOXORUBICIN; INDIUM 111; LIPOSOME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2C5; NUCLEOSOME ANTIBODY; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; GAMMA SCINTIGRAPHY; LEWIS CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOXORUBICIN; FEMALE; IMMUNOTHERAPY; LIPOSOMES; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NUCLEOSOMES;

EID: 62649125368     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp8001528     Document Type: Article

References (49)

1. Skubitz, K. M. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest. 2003, 21 (2), 167-176.
2. Tejada-Berges, T.; Granai, C. O.; Gordinier, M.; Gajewski, W. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev. Anticancer Ther. 2002, 2 (2), 143-150.
3. Harris, L.; et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002, 94 (1), 25-36.
4. Gabizon, A. A.; Lyass, O.; Berry, G. J.; Wildgust, M. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest. 2004, 22 (5), 663-669.
5. Safra, T.; et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol. 2000, 11 (8), 1029-1033.
6. Gabizon, A.; Shmeeda, H.; Barenholz, Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 2003, 42 (5), 419-436.
7. Gabizon, A.; et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54 (4), 987-992.
8. Gabizon, A.; et al. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J. Drug Targeting 2002, 10 (7), 539-548.
9. Alberts, D. S.; et al. Efficacy and safety of liposomal anthracy-clines in phase I/II clinical trials. Semin. Oncol. 2004, 31 (6 Suppl. 13), 53-90.
10. Ranson, M. R.; et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J. Clin. Oncol. 1997, 15 (10), 3185-3191.
11. Lyass, O.; et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89 (5), 1037-1047.
12. Danesi, R.; et al. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin. Pharmacokinet. 2002, 41 (6), 431-444.
13. Charrois, G. J.; Allen, T. M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim. Biophys. Acta 2004, 1663 (1-2), 167-177.
14. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discovery 2005, 4 (2), 145-160.
15. Park, J. W.; et al. Tumor targeting using anti-her2 immunolipo-somes. J. Controlled Release 2001, 74 (1-3), 95-113.
16. Schiffelers, R. M.; et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Controlled Release 2003, 91(1-2), 115-122.
17. Eliaz, R. E.; Szoka, F. C., Jr. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 2001, 61 (6), 2592-2601.
18. Kobayashi, T.; et al. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int. J. Pharm. 2007, 329 (1-2), 94-102.
19. Goren, D.; et al. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 2000, 6 (5), 1949-1957.
20. Shmeeda, H.; et al. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol. Cancer Ther. 2006, 5 (4), 818-824.
21. Lee, R. J.; Low, P. S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta 1995, 1233 (2), 134-144.
22. Xiong, X. B.; et al. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm. Res. 2005, 22 (6), 933-939.
23. Xiong, X. B.; et al. Intracellular delivery of doxorubicin withRGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J. Pharm. Sci. 2005, 94 (8), 1782-1793.
24. Pastorino, F.; et al. Doxorubicin-loaded Fab′ fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 2003, 63 (1), 86-92.
25. Iakoubov, L. Z.; Torchilin, V. P. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. Oncol. Res. 1997, 9 (8), 439-446.
26. Iakoubov, L. Z.; Rokhlin, O.; Torchilin, V. P. Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. Immunol. Lett. 1995, 47 (1-2), 147-149.
27. Bell, D. A.; Morrison, B. The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. Clin. Immunol. Immunopathol. 1991, 60 (1), 13-26.
28. Le Lann, A. D.; et al. In vitro inhibition of natural-killer-mediated lysis by chromatin fragments. Cancer Immunol. Immunother. 1994, 39 (3), 185-192.
29. Wyllie, A. H. Apoptosis (the 1992 Frank Rose Memorial Lecture). Br. J. Cancer 1993, 67 (2), 205-208.
30. Torchilin, V. P.; Iakoubov, L. Z.; Estrov, Z. Therapeutic potential of antinuclear autoantibodies in cancer. Cancer Ther. 2003, 1, 179-190.
31. Jacob, L.; et al. A monoclonal anti-double-stranded DNA autoan-tibody binds to a 94-kDa cell-surface protein on various cell types via nucleosomes or a DNA-histone complex. Proc. Natl. Acad. Sci. U.S.A. 1989, 86 (12), 4669-4673.
32. Seddiki, N.; et al. Calreticulin, a potential cell surface receptor involved in cell penetration of anti-DNA antibodies. J. Immunol. 2001, 166 (10), 6423-6429.
33. Chakilam, A. R.; Pabba, S.; Mongayt, D.; Iakoubov, L. Z.; Torchilin, V. P. A single monoclonal antinuclear autoantibody with nucleosome-restricted specificity inhibits the growth of diverse human tumors in nude mice. Cancer Ther. 2004, 2 (4), 353-364.
34. Le Lann-Terrisse, A. D.; Fournie, G. J.; Benoist, H. Nucleosome-dependent escape of tumor cells from natural-killer-mediated lysis: nucleosomes are taken up by target cells and act at a postconju-gation level. Cancer Immunol. Immunother. 1997, 43 (6), 337-344.
35. Elbayoumi, T. A.; Pabba, S.; Roby, A.; Torchilin, V. P. Antinu-cleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J. Liposome Res. 2007, 17 (1), 1-14.
36. Torchilin, V. P.; Lukyanov, A. N.; Gao, Z.; Papahadjopoulos-Sternberg, B. Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs. Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (10), 6039-6044.
37. Lukyanov, A. N.; Elbayoumi, T. A.; Chakilam, A. R.; Torchilin, V. P. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Controlled Release 2004, 100 (1), 135-144.
38. Elbayoumi, T. A.; Torchilin, V. P. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur. J. Pharm. Sci. 2007, 32 (3), 159-168.
39. Torchilin, V. P.; et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophe-nylcarbonyl groups. Biochim. Biophys. Acta 2001, 1511 (2), 397-411.
40. Elbayoumi, T. A.; Torchilin, V. P. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur. J. Nucl. Med. Mol. Imaging 2006, 33 (10), 1196-1205.
41. Elbayoumi, T. A.; Torchilin, V. T. Tumor-targeted immuno-liposomes for delivery of chemotherapeutics and diagnostics. J. Pharm. Innovation 2008, 3 (1), 51-58.
42. Elbayoumi, T. A.; Torchilin, V. P. Tumor-specific antibody-mediated targeted delivery of Doxil® reduces the manifestation of auricular erythema side effect in mice. Int. J. Pharm. 2008, 357 (1-2), 272-279.
43. Lu, D. Y.; Xu, B.; Ding, J. Antitumor effects of two bisdiox-opiperazines against two experimental lung cancer models in vivo. BMC Pharmacol. 2004, 4 (1), 32.
44. Nakamura, K.; et al. Inhibitory effect of Cordyceps sinensis on spontaneous liver metastasis of Lewis lung carcinoma and B16 melanoma cells in syngeneic mice. Jpn. J. Pharmacol. 1999, 79 (3), 335-341.
45. Charrois, G. J.; Allen, T. M. Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity. J. Pharmacol. Exp. Ther. 2003, 306 (3), 1058-1067.
46. Uziely, B.; et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 1995, 13 (7), 1777-1785.
47. Lotem, M.; et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch. Dermatol. 2000, 136 (12), 1475-1480.
48. Brignole, C.; et al. Development of Fab′ fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett. 2003, 197 (1-2), 199-204.
49. Iakoubov, L. Z.; Torchilin, V. P. Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. Cancer Detect. Prev. 1998, 22 (5), 470-475.